Trial Profile

A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zanubrutinib (Primary)
Indications Marginal zone B-cell lymphoma
Focus Registrational; Therapeutic Use
Acronyms MAGNOLIA
Sponsors BeiGene

Most Recent Events

15 Jun 2023 Final analysis presented at the 28th Congress of the European Haematology Association.
15 Jun 2023 Results of pooled analysis from NCT03846427 and NCT02343120 assessing unanchored MAIC to estimate the comparative efficacy of ZANU versus IBRU in R/RMZL presented at the 28th Congress of the European Haematology Association
06 Jun 2023 Results assessing matching-adjusted indirect comparison to estimate efficacy of zanubrutinib versus ibrutinib in relapsed/refractory marginal zone lymphoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com